MedicaidApril 1, 2021
Clinical criteria updates notification December 2020
On December 18, 2020, and December 22, 2020, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross. These policies were developed, revised or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: newly published criteria
- Revised: addition or removal of medical necessity requirements, new document number
- Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other members of your practice and office staff.
Note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
Effective date |
Document number |
Clinical Criteria title |
New or revised |
June 1, 2021 |
ING-CC-0185* |
Oxlumo (lumasiran) |
New |
June 1, 2021 |
ING-CC-0184* |
Danyelza (naxitamab-gqgk) |
New |
June 1, 2021 |
ING-CC-0154 |
Givlaari (givosiran) |
Revised |
June 1, 2021 |
ING-CC-0124 |
Keytruda (pembrolizumab) |
Revised |
June 1, 2021 |
ING-CC-0002 |
Colony Stimulating Factor Agents |
Revised |
June 1, 2021 |
ING-CC-0032* |
Botulinum Toxin |
Revised |
PUBLICATIONS: April 2021 Anthem Blue Cross Provider News - California
To view this article online:
Or scan this QR code with your phone